Supernus Pharmaceuticals, Inc. SUPN
We take great care to ensure that the data presented and summarized in this overview for SUPERNUS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SUPN
View all-
Black Rock Inc. New York, NY10.4MShares$332 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.1 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.1 Million0.11% of portfolio
-
State Street Corp Boston, MA2.19MShares$70 Million0.0% of portfolio
-
Stephens Investment Management Group LLC1.75MShares$56 Million0.88% of portfolio
-
Polar Capital Holdings PLC London, X01.69MShares$54 Million0.38% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.6MShares$51.1 Million0.09% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.6MShares$51.1 Million0.14% of portfolio
Latest Institutional Activity in SUPN
Top Purchases
Top Sells
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Insider Transactions at SUPN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,017
-7.62%
|
$64,544
$32.06 P/Share
|
Mar 10
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+12.54%
|
-
|
Mar 10
2025
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,805
-1.67%
|
$537,760
$32.06 P/Share
|
Mar 10
2025
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+3.35%
|
-
|
Mar 07
2025
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,581
-1.87%
|
$724,659
$39.11 P/Share
|
Mar 07
2025
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,640
+3.75%
|
-
|
Mar 07
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
1,356
-8.21%
|
$52,884
$39.11 P/Share
|
Mar 07
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+13.72%
|
-
|
Mar 05
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,485
-3.61%
|
$49,005
$33.05 P/Share
|
Mar 05
2025
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,193
-8.11%
|
$105,369
$33.05 P/Share
|
Mar 05
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,468
-4.61%
|
$48,444
$33.05 P/Share
|
Mar 05
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
1,892
-4.15%
|
$62,436
$33.05 P/Share
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,885
-8.67%
|
$112,515
$39.48 P/Share
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.69%
|
-
|
Feb 23
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+10.12%
|
-
|
Feb 23
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+8.1%
|
-
|
Feb 23
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+15.07%
|
-
|
Feb 23
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
1,875
+12.69%
|
-
|
Feb 22
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+9.64%
|
-
|
Feb 22
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.42%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 43.2K shares |
---|---|
Exercise of conversion of derivative security | 569K shares |
Payment of exercise price or tax liability | 88K shares |
---|---|
Open market or private sale | 386K shares |